Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00652925 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 225
- Enrollment target
NCT00652925 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 225 participants.
The verdict
NCT00652925, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 225 participants
- Enrollment target
Study Summary
To study Celebrex versus naproxen to see if it decreases symptoms of juvenile arthritis such as pain and swelling.
Interventions
- DRUG Celecoxib
- DRUG Naproxen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2002-10 |
| Est. Completion | 2005-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00652925
The ClinicalTrials.gov registry entry for NCT00652925 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Celecoxib is the first listed.
NCT00652925 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00652925 about?
NCT00652925 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA". To study Celebrex versus naproxen to see if it decreases symptoms of juvenile arthritis such as pain and swelling.
What is the current status of trial NCT00652925?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 225 participants. The study started on 2002-10. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00652925?
The interventions under investigation include: Celecoxib (DRUG), Naproxen (DRUG).
Who is sponsoring clinical trial NCT00652925?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.